clinical trial · NCT04241068
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Biogen·phase3·terminated·n = 1,696
Alzheimer's DiseaseAducanumab
brief summary
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
started
Mar 2, 2020
primary completion
Jul 22, 2024
completion
Jul 22, 2024
last updated
Feb 21, 2025
official title
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol